22 mar: Novo Nordisk/Deutsche: Sænker anbefaling til "sælg"
22 mar: ECB kan droppe krisefond på 40 mia. euro - avis
22-03-2012 08:20:51

Dräger buys back 41.1 percent of participation certificates

Drägerwerk AG & Co. KGaA /

Dräger buys back 41.1 percent of participation certificates

. Processed and transmitted by Thomson Reuters ONE.

The issuer is solely responsible for the content of this announcement.

Lübeck - Drägerwerk AG & Co. KGaA has bought back 41.1 percent of its issued participation certificates and now intends to redeem the purchased participation certificates. The participation certificates bought back have a total purchase price of EUR 122.1 million. This transaction decreases the equity ratio by about three percentage points; earnings per share on imputed actual full distribution will improve by 19 percent (based on the consolidated group financial statement 2011).

Improved capital structure

"Thanks to the successful buy-back, we have come a great deal closer to our goal of improving our capital structure. As such, we would like to thank all participation certificate holders that have accepted our offer," says Stefan Dräger, Chairman of the Executive Board of Drägerwerk Verwaltungs AG.

Premium for participation certificate holders was 26 percent

On February 15, 2012, Dräger requested that holders of participation certificate series A, K and D (series A: ISIN DE0005550651, WKN 555065; series K: ISIN DE0005550677, WKN 555067; series D: ISIN DE0005550719, WKN 555071) offer Dräger their participation certificates at a price of EUR 210 per share. The buy-back price named by Dräger corresponded to a premium of 26 percent on the average participation certificate price in the three months prior to the offer on February 15, 2012.

Disclaimer

This press release contains statements on the future development of Dräger Group. These forward-looking statements are based on the current expectations, presumptions, and forecasts of the Executive Board as well as the information available to it to date and have been prepared to the best of its knowledge and belief. No guarantee or liability for the occurrence of the future developments and results specified can be assumed in respect of such forward-looking statements. Rather, the future developments and results are dependent on a number of factors. They entail risks and uncertainties beyond the Company's control and are based on assumptions which could prove to be incorrect. Notwithstanding any legal requirements to adjust forecasts, Dräger does not assume any obligation to update the forward-looking statements contained in this report. Please go to Investor Relations / Financial Calendar at www.draeger.com for information on all important financial dates.

Contact

Corporate Communications:

Melanie Kamann

Tel. +49 451 882-3998

melanie.kamann@draeger.com

Investor Relations:

Vanina Hoffmann

Tel. +49 451 882-2685

vanina.hoffmann@draeger.com

Drägerwerk AG & Co. KgaA

Moislinger Allee 53-55

23542 Lübeck, Germany

www.draeger.com

Press release (PDF)


This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the

information contained therein.

Source: Drägerwerk AG & Co. KGaA via Thomson Reuters ONE

HUG#1596398

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
26 jul
 
Pouli,   Forum er i den grad domineret af børn, studerende, ludomaner, buffet-wannabees and what hav..
24
28 jul
GEN
Der er lidt nyt fra Morphosys angående deres CD38 antistof - det lader heldigvis til at gå lidt lang..
17
30 jul
 
Jeg er helt vild med vendingen "og investere mine penge i aktier ud fra en strategi jeg mener vil sl..
14
29 jul
FING-B
XO/Sologstrand, Mackeith, Vildum, Swiftnick og andre FING-skeptikere   1) Er vi enige i, at markedet..
13
28 jul
 
Dejligt at der er nogen som kan svare "sobert" på et stillet spørgsmål.   Svaret kan indeholde ironi..
12
01 aug
GEN
Rygterne siger At den hemmelige partner er Gilead. De er jo et af vardens største biotekselskaber de..
11
29 jul
BIOPOR
I er tydeligvis enormt begavede og succesfulde alle tre. Men kunne det være muligt for jer at måle j..
10
27 jul
 
Jeg har opdateret mine udbyttelister med tilbagekøb.   http://www.proinvestor.com/boards/69564/    
10
28 jul
VELO
28/07/2014 08:30:00 - OMX Copenhagen, News     VELO: Veloxis Pharmaceuticals A/S - Envarsus ® får ..
9
01 aug
 
Steinbock3, som bekendt findes der................................................................ i..
8

Atlantic Petroleum producerede 19.000 tønder i juli

01-08-2014 15:21:52
Atlantic Petroleum havde i juli en gennemsnitlig daglig produktion af 613 tønder olieækvivalenter, og produktionen for måneden nåede dermed 19.000 fra de tre fe..

Novo: Tyske myndigheder ser ikke fordele ved Tresiba - NY

01-08-2014 13:47:20
Novo Nordisk er løbet ind i et nederlag i Tyskland.De tyske sundhedsmyndigheders rådgivende institut (IQWIG) er fredag kommet med en rapport, hvor det konkluder..

Mærsk: Vigtigt rateindeks vender kurven og stiger

01-08-2014 11:23:32
Det vigtige indeks over containerfragtrater, SCFI-indekset, har efter flere ugers fald vendt udviklingen og er steget 12,7 pct. i denne uge.Indekset, som viser ..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Aktier/middag: Giftig cocktail trækker ned
2
Aktier/tendens: Faldene vil ebbe ud
3
Aktier/Nordnet: Private køber Pandora og Vestas
4
Brøndby-formand: Vi går efter Agger nu
5
Aktier/åbning: Genmab og Carlsberg tager teten i svært marked
Euroinvestor i andre lande: Euroinvestor.com | Euroinvestor.se | Euroinvestor.no | Euroinvestor.fr | Forexinvestor.com| Wisselkoersen.nl | Valuta.se | Valutaveksel.no | Divisas.es | Valute.it
Copyright Euroinvestor A/S 2014  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
2. august 2014 06:28:45
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20140731.2 - EUROWEB5 - 2014-08-02 06:28:45 - 2014-08-02 06:28:45 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x